<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: investors</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'investors'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22investors%22&t=%22investors%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 02:08:46 +0100</lastBuildDate>
        <item>
            <title>Pfizer Inc: Working Together for a Healthier Investor™</title>
            <link>http://www.medworm.com/index.php?rid=4433324&amp;cid=t_103934_150_f&amp;fid=34889&amp;url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2011%2F02%2Fpfizer-inc-working-together-for.html</link>
            <description>Pfizer's corporate slogan -- Working Together for a Healthier World™ -- may be &quot;commercially unpromising&quot; and in need of restructuring. &quot;[Pfizer's research] employees worldwide - along with patients awaiting breakthroughs in therapeutic areas that have been deemed commercially unpromising such as urology, allergies and respiratory ailments - are the losers in a reshuffling of priorities by the world’s largest drugmaker,&quot; reported the Financial Times (here).Pfizer's incoming chief Ian Read plans to continue along the shareholder-pleasing path established by Jeff Kindler, the company's outgoing CEO.During the past 5 years, &quot;Pfizer returned about $45bn in cash to shareholders while continuing headcount-shredding mergers, most recently with Wyeth,&quot; said FT. &quot;Now it will cut an additional $...</description>
            <author>Pharma Marketing Blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4433324</comments>
            <pubDate>Thu, 03 Feb 2011 12:51:00 +0100</pubDate>
            <guid isPermaLink="false">4433324</guid>        </item>
        <item>
            <title>Angel Investors</title>
            <link>http://www.medworm.com/index.php?rid=3499056&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FiQLh1mV3D4U%2F</link>
            <description>By Chris EdwardsThe Wall Street Journal has an important editorial today on how the financial &amp;#8220;reform&amp;#8221; bill being considered by Congress could help kill the angel investment industry in the United States.
Burying angels under new regulations would be part of a one-two knock-out blow for this group of more than 300,000 higher-income Americans who invest directly into start-up companies. The Obama administration&amp;#8217;s tax-increase policies would be the other blow, as I testified to the Senate earlier this year. 
Angels have played a crucial role in America&amp;#8217;s dynamic job-creating economy over the decades. Policymakers would be absolutely crackers to screw up such a successful part of our innovation economy. (Source: Cato-at-liberty)</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3499056</comments>
            <pubDate>Thu, 22 Apr 2010 19:36:27 +0100</pubDate>
            <guid isPermaLink="false">3499056</guid>        </item>
        <item>
            <title>Moody’s Caves In to Political Pressure on Municipal Bonds</title>
            <link>http://www.medworm.com/index.php?rid=3378459&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FC2a-Db-bt_8%2F</link>
            <description>By Mark A. CalabriaMoody&amp;#8217;s has announced that it will change its methods for rating debt issued by state and local governments.  Politicians have argued that its current ratings ignore the historically low default rate of municipal bonds, resulting in higher interest rates being paid on muni debt, or so argue the politicians.
First this argument ignores that the market determines the cost of borrowing, not the rating.  And while ratings are considered by market participants, one can easily find similarly rated bonds that trade at different yields.
Second, while ratings should give some weight to historical performance, far more weight should be given to expected future performance.  Regardless of how say California-issued debt has performed in the past, does anyone doubt that Cali...</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3378459</comments>
            <pubDate>Wed, 17 Mar 2010 20:03:58 +0100</pubDate>
            <guid isPermaLink="false">3378459</guid>        </item>
        <item>
            <title>Ban on Short Sales Benefits Banks and Hurts Investors</title>
            <link>http://www.medworm.com/index.php?rid=3306828&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FrH1K8GAlV04%2F</link>
            <description>By Mark A. CalabriaToday, in what seems like an endless string of 3-2 votes, the SEC moved to restrict the ability of investors to short stocks, claiming that such restrictions would restore stability and protect our financial system.  The truth couldn’t be more different.  Short sellers have long been the first, and often only, voice raising questions about corporate fraud and mismanagement.  For instance, shorts exposed the fraud at Enron, WorldCom and other companies while the SEC largely slept.
Bush’s SEC, lead by former Congressman Chris Cox banned the shorting of various financial industry stocks during the crisis.  The SEC then, as now, would have us believe that Bear, Lehman, AIG, Fannie, Freddie and others were not the victims of their own mismanagement, but rather vict...</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3306828</comments>
            <pubDate>Wed, 24 Feb 2010 18:50:16 +0100</pubDate>
            <guid isPermaLink="false">3306828</guid>        </item>
        <item>
            <title>Investors Have Questions About Pharma's Online Spending in 2010 and Beyond</title>
            <link>http://www.medworm.com/index.php?rid=3097061&amp;cid=t_103934_150_f&amp;fid=34889&amp;url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F12%2Finvestors-have-questions-about-pharmas.html</link>
            <description>Investors who own stocks or who are thinking of buying stocks of major online Health sites are worried. They have lots of questions about FDA's plans for regulating drug promotion on the Internet. As we know, when FDA regulates, markets react. When FDA sent out those 14 NOV letters, for example, branded paid search engine marketing by pharma experienced a &quot;Prompt, Precipitous, &amp; Prolonged&quot; Plummet (see here). That could have been just a coincidence; I have heard that Google is worried about an overall decline in paid search engine advertising.Anyway, an Internet research team at a major regional brokerage and investment banking firm that provides investment advisory services to individual investors and professional money managers invited me to speak to some of their clients via conference ...</description>
            <author>Pharma Marketing Blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3097061</comments>
            <pubDate>Wed, 16 Dec 2009 19:54:00 +0100</pubDate>
            <guid isPermaLink="false">3097061</guid>        </item>
        <item>
            <title>Genzyme Adds Board Member As Troubles Mount</title>
            <link>http://www.medworm.com/index.php?rid=3075766&amp;cid=t_103934_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FG8lB7BqRTC8%2F</link>
            <description>After months of serious problems, Genzyme added an independent director to its board under pressure from Relational Investors, an activist hedge fund, The Wall Street Journal reports. The biotech added Bob Bertolini, who was chief financial officer at Schering-Plough before it was acquired by Merck (see statement).
Genzyme has endured nothing but trouble this year as quality control problems forced the biotech to suspend shipments of key products for such ailments as Gaucher&amp;#8217;s and Fabry diseases, and the subsequent shortages prompted the FDA to allow rivals to jumpstart plans to produce their own meds to fill the void (see coverage here and here). 

The difficulties have shaken confidence in Genzyme management, leading to speculation the board would be pressured to make changes. Addi...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3075766</comments>
            <pubDate>Thu, 10 Dec 2009 11:35:30 +0100</pubDate>
            <guid isPermaLink="false">3075766</guid>        </item>
        <item>
            <title>Bernanke Rules?</title>
            <link>http://www.medworm.com/index.php?rid=2625963&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2Fj9AVWzqNpdc%2F</link>
            <description>In today&amp;#8217;s Wall Street Journal, Fed Chairman Ben Bernanke has outlined &amp;#8220;The Fed&amp;#8217;s Exit Strategy.&amp;#8221; He tells the reader how the central bank will avoid an inflation of historic proportions resulting from all the money and credit it has injected into the economy. All of the strategies he outlines are technically feasible ways for the Fed to implement monetary restraint.
The op-ed has an air of a classroom exercise, however, rather than a practical central-bank strategy. Much of the article is devoted to explaining how the Fed can now pay interest on reserves, and how it could raise that interest rate so as to dissuade commercial banks from lending the reserves out. It could do that, but what would that rate need to be in order to meet a private bank&amp;#8217;s threshold r...</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2625963</comments>
            <pubDate>Tue, 21 Jul 2009 15:15:52 +0100</pubDate>
            <guid isPermaLink="false">2625963</guid>        </item>
        <item>
            <title>Bernie Madoff and Government Fraud</title>
            <link>http://www.medworm.com/index.php?rid=2610878&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FgN5JyxMcyeE%2F</link>
            <description>In an op-ed Chris Edwards and I wrote for National Review Online yesterday, we shed light on the $100 billion or more in government subsidies pilfered by recipients through fraud and abuse:
Every year, criminals and cheats pilfer over $100 billion — that&amp;#8217;s $40 billion more than Bernie Madoff scammed off his investors — in federal benefits to which they are not legally entitled. Medicare, Medicaid, food stamps, refundable tax credits, and many other programs are targets for looting.
Chris and I focused on fraud and abuse perpetrated by the recipients of taxpayer largesse, and Bernie Madoff made for a good comparison. But as the great economist and Cato adjunct scholar Robert Higgs also pointed out yesterday, &amp;#8220;Bernie Madoff Was Only a Petty Crook Compared with Uncle Sam.&amp;#82...</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2610878</comments>
            <pubDate>Thu, 16 Jul 2009 20:51:33 +0100</pubDate>
            <guid isPermaLink="false">2610878</guid>        </item>
        <item>
            <title>SEC Favors Special Interests in New Corporate Elections Rule</title>
            <link>http://www.medworm.com/index.php?rid=2570377&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FQSNrgT7mcy8%2F</link>
            <description>Yesterday, the SEC repealed a long-standing rule which allowed brokers to vote shares on behalf of their investors, unless they obtained written directions from each individual investors.  While investors have long been able to direct the voting of their shares, many do not take the time to.  In these cases, the brokers vote those shares, after all they are the agents of the investors and are hired to act on their behalf.
The direct effect of the rule will be to reduce the voting weight of retail investors, as represented by their brokers.  In voting against the rule, SEC Commissioner Kathy Casey raised the point that the rule would skew voting toward large institutional investors and away from little retail investors.
What did the large institutions investors have to say?  As reported...</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2570377</comments>
            <pubDate>Thu, 02 Jul 2009 17:52:31 +0100</pubDate>
            <guid isPermaLink="false">2570377</guid>        </item>
        <item>
            <title>New Video Explains Why Soak-the-Rich Tax Increases Are Misguided</title>
            <link>http://www.medworm.com/index.php?rid=2477534&amp;cid=t_103934_87_f&amp;fid=36438&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2Fq16t_eoGPbY%2F</link>
            <description>The Obama Administration is proposing higher taxes on just about everyone and everything, but one common theme is that most of the tax increases are being portrayed as ways of fleecing the so-called rich. This new video, narrated by yours truly, provides five reasons why the economy will suffer if entrepreneurs and investors are hit with punitive taxes.

As always, any feedback on message and style would be appreciated. (Source: Cato-at-liberty)</description>
            <author>Cato-at-liberty</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2477534</comments>
            <pubDate>Mon, 15 Jun 2009 20:46:53 +0100</pubDate>
            <guid isPermaLink="false">2477534</guid>        </item>
        <item>
            <title>Pushing Doctors into a &quot;Dual Mandate&quot; and the &quot;Attack on Doctors' Hippocratic Oath&quot;</title>
            <link>http://www.medworm.com/index.php?rid=2382300&amp;cid=t_103934_87_f&amp;fid=34825&amp;url=http%3A%2F%2Fwww.wesleyjsmith.com%2Fblog%2F2009%2F05%2Fpushing-doctors-into-dual-mandate-and.html</link>
            <description>Physicians are being pushed steadily into an untenable position. On one hand, they are professionally obligated to render optimal care to each patient based on individual need. On the other hand, they are increasingly being looked to by bureaucrats and bioethicists as serving another role--for society--as the rationing arms of cost control.The effect of this would require doctors to give optimal care to some patients but not others, probably based on mandatory invidiously discriminatory categories of age, disability, perhaps even politically incorrect lifestyles such as smoking and obesity (but never, for example culturally acceptable risky behaviors like promiscuity). This dual mandate, if adopted, would place doctors and other health care professionals in a terrible conflict of interest-...</description>
            <author>Secondhand Smoke</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2382300</comments>
            <pubDate>Fri, 01 May 2009 16:23:00 +0100</pubDate>
            <guid isPermaLink="false">2382300</guid>        </item>
        <item>
            <title>Daily Strength Sold to HSW International</title>
            <link>http://www.medworm.com/index.php?rid=2021408&amp;cid=t_103934_109_f&amp;fid=34750&amp;url=http%3A%2F%2Fpsychcentral.com%2Fblog%2Farchives%2F2008%2F12%2F08%2Fdaily-strength-sold-to-hsw-international%2F</link>
            <description>Daily Strength, a health social networking site that likes to boast about the number of communities it hosts (regardless of the number of actual active members it has), has been sold to an international corporation called HSW International. Never heard of them? Nor had I:
	
HSW International, Inc., an online publishing company, develops and operates Internet businesses that are focused on providing consumers with digital content database [sic]. It primarily focuses on the online publishing of localized and translated Chinese and Brazilian editions of the HSW Internet site [specifically, they provide two foreign language versions of the HowStuffWorks.com website]. The company operates a Brazilian Internet Web site, hsw.uol.com.br, which has approximately 3,500 articles, including articles f...</description>
            <author>World of Psychology</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2021408</comments>
            <pubDate>Mon, 08 Dec 2008 22:19:59 +0100</pubDate>
            <guid isPermaLink="false">2021408</guid>        </item>
        <item>
            <title>Brain Fitness Webinar Series</title>
            <link>http://www.medworm.com/index.php?rid=1440462&amp;cid=t_103934_122_f&amp;fid=36582&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FSharpBrains%2F%7E3%2F289188628%2F</link>
            <description>I have been travelling much over the last 2 weeks to speak at a number of conferences and universities. I promised I would be sharing some of the key highlights, but we have decided to do something better to do justice to the richness and complexity of the field we cover. We are going to launch an experiment: a Brain Fitness Webinar Series.
This inaugural Brain Fitness Webinar Series will consist of 3 free live sessions. The series covers the most fundamental advances in cognitive science and their implications for individuals, companies and organizations. And we are honored to have John Medina lead of the sessions!
Each event is independent, in topic and in registration process.
Webinar #1: In “The State of the Brain Fitness Software Market, 2008,” I will provide an overview of the s...</description>
            <author>SharpBrains</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1440462</comments>
            <pubDate>Tue, 13 May 2008 05:08:45 +0100</pubDate>
            <guid isPermaLink="false">1440462</guid>        </item>
        <item>
            <title>Seeking Cash to Launch a Brainchild?</title>
            <link>http://www.medworm.com/index.php?rid=1021381&amp;cid=t_103934_109_f&amp;fid=35677&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FBrainBasedBusiness%2F%7E3%2F183660093%2Fseeking_cash_for_your_brainchi.html</link>
            <description>In the last few days I&amp;rsquo;ve spoken hard core cash &amp;hellip; &amp;nbsp;to people across several fields. Some spoke of steady revenue streams &amp;hellip; that pay their daily costs &amp;hellip; without much more. Others hoped that dollars would come to them &amp;hellip; before their crunch set in too deep. A smaller group spoke of searching out financial streams &amp;hellip; to fund&amp;nbsp;some promising brainchild. Interestingly, this brainchild bunch &amp;hellip; was often stopped short &amp;nbsp;by what they saw as financial flaws.They hadn&amp;rsquo;t found any fortunes reportedly risked by angel investors, in spite of entrepreneurs who say it&amp;#39;s there. They&amp;rsquo;d wasted money on firms with quick fixes that never came. They&amp;rsquo;d exhausted their own good credit &amp;hellip; which allowed them better interest rates...</description>
            <author>BrainBasedBusiness</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1021381</comments>
            <pubDate>Mon, 12 Nov 2007 17:11:28 +0100</pubDate>
            <guid isPermaLink="false">1021381</guid>        </item>
        <item>
            <title>Obvious, Redundant, In Your Face Diabetic Research From Me To You</title>
            <link>http://www.medworm.com/index.php?rid=828447&amp;cid=t_103934_134_f&amp;fid=36049&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FDiabetesNotes%2F%7E3%2F149188995%2F</link>
            <description>I have to do it this morning. I have been fighting the urge for over 2 weeks now. Every morning as I wade through all the new and updated diabetes information, I come across the most obvious, ridiculous almost &amp;#8220;slap in your face&amp;#8221; kind of findings.  So I am going to share a few with you this very fine morning. Now don&amp;#8217;t laugh too hard! To think that our tax dollars and private investors fund such research is mind blowing&amp;#8230;
Staying active &amp;#8212; getting regular physical exercise, helps prevent and control diabetes, advises a U.S. expert. 
Researchers have found new evidence that soft drinks sweetened with high-fructose corn syrup (HFCS) may contribute to the development of diabetes, particularly in children. In a laboratory study of commonly consumed carbonated bevera...</description>
            <author>Diabetes Notes</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=828447</comments>
            <pubDate>Wed, 29 Aug 2007 01:26:20 +0100</pubDate>
            <guid isPermaLink="false">828447</guid>        </item>
        <item>
            <title>Obvious, Redundent, In Your Face Diabetic Research From Me To You</title>
            <link>http://www.medworm.com/index.php?rid=825592&amp;cid=t_103934_134_f&amp;fid=36049&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FDiabetesNotes%2F%7E3%2F149188995%2F</link>
            <description>I have to do it this morning. I have been fighting the urge for over 2 weeks now. Every morning as I wade through all the new and updated diabetes information, I come across the most obvious, ridiculous almost &amp;#8220;slap in your face&amp;#8221; kind of findings.  So I am going to share a few with you this very fine morning. Now don&amp;#8217;t laugh too hard! To think that our tax dollars and private investors fund such research is mind blowing&amp;#8230;
Staying active &amp;#8212; getting regular physical exercise, helps prevent and control diabetes, advises a U.S. expert. 
Researchers have found new evidence that soft drinks sweetened with high-fructose corn syrup (HFCS) may contribute to the development of diabetes, particularly in children. In a laboratory study of commonly consumed carbonated bevera...</description>
            <author>Diabetes Notes</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=825592</comments>
            <pubDate>Tue, 28 Aug 2007 11:54:34 +0100</pubDate>
            <guid isPermaLink="false">825592</guid>        </item>
        <item>
            <title>MethylGene and Pharmion Expand Collaboration on Epigenetic Therapies</title>
            <link>http://www.medworm.com/index.php?rid=811183&amp;cid=t_103934_131_f&amp;fid=34990&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fepigeneticsnews%2F%7E3%2F146248053%2F</link>
            <description>MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a &amp;#8220;research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.&amp;#8221;
MethylGene and Pharmion&amp;#8217;s Class I specific HDAC inhibitor, MGCD0103, has demonstrated efficacy in a number of tumor types, and the sirtuins represent potentially attractive novel cancer targets within a related family of enzymes. Sirtuins (including SIRT1) have been shown to deacetylate histone proteins and numerous transcription factors, leading to promotion of normal cell survival and aberrant gene silencing in cancer cells. Inhibition of sirtuins allows reexpression of silenc...</description>
            <author>Epigenetics News</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=811183</comments>
            <pubDate>Mon, 20 Aug 2007 20:40:45 +0100</pubDate>
            <guid isPermaLink="false">811183</guid>        </item>
        <item>
            <title>SensiGen Secures Option for Licensing Lupus Biomarkers</title>
            <link>http://www.medworm.com/index.php?rid=728456&amp;cid=t_103934_131_f&amp;fid=34990&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fepigeneticsnews%2F%7E3%2F132788317%2F</link>
            <description>Ann Arbor, Michigan-based SensiGen LLC has acquired an option to license a set of epigenetic biomarkers for the early detection and monitoring of lupus from the University of Michigan. The technology consists of &amp;#8220;a patented panel of proprietary biomarkers for epigenetic variations of genes uniquely associated with Lupus along with related research assays.
We previously covered the epigenetics of Systemic Lupus Erythematosus (SLE) in June 2006 when a review article (published by researchers at the University of Michigan) concisely described the &amp;#8220;epigenetic face&amp;#8221; of the disease:
For instance, drugs that demethylate T cells, such as 5-azacytidine, are used by researchers to induce lupus-like disease in mice. Additionally, demethylation of certain gene promoter and regulatory...</description>
            <author>Epigenetics News</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=728456</comments>
            <pubDate>Wed, 11 Jul 2007 22:35:38 +0100</pubDate>
            <guid isPermaLink="false">728456</guid>        </item>
        <item>
            <title>Global Epigenomics Market to Reach $4.1 Billion by 2012</title>
            <link>http://www.medworm.com/index.php?rid=603417&amp;cid=t_103934_131_f&amp;fid=34990&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fepigeneticsnews%2F%7E3%2F115923570%2F</link>
            <description>&amp;#8220;$4.1 Billion by 2012&amp;#8243; is the major finding of a market report on the global epigenomics market published by BCC Research. The report identified three key market segments that will be commercially important in the field of epigenomics in the next 5 years: research tools, cancer diagnostics, and cancer therapeutics.
There are three major highlights from the report (which I have not read in its entirety due to its cost):

 The global market for epigenomics was $161.8 million in 2005 and $263.2 million in 2006. The market will cross $385 million by 2007 and at a compound annual growth rate (CAGR) of 60.4% will reach nearly $4.1 billion by 2012.
Drug applications for epigenetics are by far the largest sector of the market. These drugs will hold 61% of the total global market in 200...</description>
            <author>Epigenetics News</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=603417</comments>
            <pubDate>Fri, 11 May 2007 16:05:01 +0100</pubDate>
            <guid isPermaLink="false">603417</guid>        </item>
        <item>
            <title>Epigenetics Attracting Attention from Investors</title>
            <link>http://www.medworm.com/index.php?rid=485885&amp;cid=t_103934_131_f&amp;fid=34990&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fepigeneticsnews%2F%7E3%2F101171313%2F</link>
            <description>I&amp;#8217;ve talked before about e-mails I commonly receive from consultants, investors, and others regarding investment ideas of companies that are poised to take advantage of the research being done in epigenetics. I thought I would share a recent example of one such e-mail:
Hello Trevor-
   Congrats on getting this site up. I first read about epigenetics in Discover magazine last year. It&amp;#8217;s very interesting and intuitively seems more correct than &amp;#8220;traditional&amp;#8221; ideas about evolution. It&amp;#8217;s a relief to have research that would validate the rise of cancers and &amp;#8220;DNA gone mad&amp;#8221; accumulated from the many internal and external toxins we have exposed ourselves to in just the past 3 (or so) generations.This brings a sense of continuity and a more holistic element ...</description>
            <author>Epigenetics News</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=485885</comments>
            <pubDate>Mon, 12 Mar 2007 17:47:33 +0100</pubDate>
            <guid isPermaLink="false">485885</guid>        </item>
        <item>
            <title>Potential Conflict of Interest at NIEHS</title>
            <link>http://www.medworm.com/index.php?rid=485887&amp;cid=t_103934_131_f&amp;fid=34990&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2Fepigeneticsnews%2F%7E3%2F100018439%2F</link>
            <description>The National Institutes of Environmental Health Sciences (NIEHS) is under fire. Effect Measure, a blog written anonymously by public health experts and practitioners, has written a critical review of David Schwartz&amp;#8217;s two year term as director of the NIEHS:
Schwartz, like other Bush appointees, has a penchant for outsourcing public functions to private concerns, and under his boss, NIH Director Elias Zerhouni, even the peer review function was put out for bids. Schwartz has been dismantling the flagship environmental health scientific journal, Environmental Health Perspectives (EHP), moving to outsource it, gut its news and comment sections and eliminate the foreign language editions. EHP is an open access journal, but if it is outsourced it may not remain that way. The biggest losers...</description>
            <author>Epigenetics News</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=485887</comments>
            <pubDate>Wed, 07 Mar 2007 17:23:05 +0100</pubDate>
            <guid isPermaLink="false">485887</guid>        </item>
    </channel>
</rss>

